An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
LEO Pharma acquires Tanabe Pharma
PRIVATESep 18, 2026•about 4 hours ago
Acquiring Company
LEO Pharma
Acquired Company
Tanabe Pharma
New JerseyOsakaBiotechnologyHealth CareMedicalManufacturingBiotechnologyHealth CarePharmaceutical
Description
LEO Pharma has announced the closure of its acquisition from Tanabe Pharma. This acquisition aligns with its strategic focus on dermatology. Additionally, the FDA has accepted the NDA for Dersimelagon with priority review. This event marks a significant milestone for LEO Pharma's portfolio expansion.
Company Information
Company
LEO Pharma
Location
New Jersey, United States
About
LEO Pharma Inc. is a global leader in medical dermatology, dedicated to improving patient outcomes in skin disease. The company focuses on developing treatments and raising awareness for various skin conditions, including chronic hand eczema. LEO Pharma emphasizes the importance of patient voice in healthcare and aims to enhance the standard of care for patients living with skin diseases. Their newly launched 'Talk to the Hand' campaign seeks to educate healthcare providers on the impact of chronic hand eczema.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment LEO Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Tanabe Pharma?
Tanabe Pharma was acquired by LEO Pharma, based in New Jersey. The deal was reported on September 18, 2026. LEO Pharma Inc. is a global leader in medical dermatology, dedicated to improving patient outcomes in skin disease. LEO Pharma is privately held and operates in Biotechnology.
When did LEO Pharma acquire Tanabe Pharma?
LEO Pharma's acquisition of Tanabe Pharma was reported on September 18, 2026. LEO Pharma has announced the closure of its acquisition from Tanabe Pharma. This acquisition aligns with its strategic focus on dermatology. Additionally, the FDA has accepted the NDA for Dersimelagon with priority review. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Tanabe Pharma do?
Tanabe Pharma, formerly known as Mitsubishi Tanabe Pharma, is a pharmaceutical company specializing in the development and manufacture of innovative drugs and generic medicines. It is privately held, operating in Manufacturing, and is based in Osaka.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
New Jersey
OsakaBiotechnologyHealth CareMedicalManufacturingBiotechnologyHealth CarePharmaceutical